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Varicella-zoster virus (VZV) reactivation is a frequent complication after allogeneic hematopoietic stem cell
transplantation (HSCT). Although previous studies have revealed that cellular immunity is important for
suppressing reactivation, the role of humoral immunity against VZV has been poorly evaluated. We analyzed
inherited polymorphisms in the immunoglobulin G (IgG) heavy chain constant regions of 50 HSCT recipient-
donor pairs to distinguish donor-derived and recipient-derived antibodies. Twelve pairs were informative
regarding the origin of IgG, since either the donors (n ¼ 3) or recipients (n ¼ 9) were homozygous null for the
IgG1m(f) allotype. In these 9 homozygous-null recipients, allotype-speciﬁc IgG against VZV were measured
by enzyme-linked immunosorbent assay and compared with measles-IgG. All 9 homozygous-null recipients
were monitored for more than 1 year after HSCT, with (n ¼ 4, localized zoster) or without (n ¼ 5) clinical VZV
disease. In 3 patients with VZV disease, donor-derived IgG against VZV was elevated between 500 to 700 days
after HSCT after the episode of VZV disease. In 1 patient who suffered from VZV disease just before HSCT,
donor-derived VZV IgG was elevated within 3 months after HSCT. On the other hand, 2 patients who received
reduced-intensity conditioning (RIC) transplantation from an IgG1m(f) null donor maintained recipient-
derived IgG against VZV for more than 1 year, whereas it was decreased within 3 months in 1 recipient
who received conventional conditioning. In conclusion, the production of anti-VZV IgG by recipient plasma
cells persists long after RIC. In patients without symptomatic VZV reactivation, donor-derived anti-VZV IgG
did not reach titers comparable to those measured in healthy virus carriers.
 2013 American Society for Blood and Marrow Transplantation.BACKGROUND On the other hand, the role of humoral immunity against
Varicella-zoster virus (VZV) reactivation is a frequent
complication after allogeneic hematopoietic stem cell trans-
plantation (HSCT). It is sometimes disseminated and results
in high mortality [1-3]. The incidence of VZV reactivation
within 1 year after autologous and allogeneic HSCT ranges
from 13% to 55% [3]. In a retrospective study of 100 consec-
utive allogeneicHSCTpatients, 41% developed aVZV infection
at a median of 227 (45 to 346) days after HSCT [2]. Tomonari
et al. reported that the cumulative incidence of VZV reac-
tivation after cord blood transplantation (CBT) was 80% [4].
This extremely high incidence might result from the imma-
ture nature of cord blood lymphocytes.
Many previous studies have shown that cellular immu-
nity is important for suppressing VZV reactivation [5-9]. VZV
memory T cells can usually be detected by 9 to 12 months
after HSCT and are correlated with a reduction in the risk and
complications of VZV disease [6]. The reconstitution of
cellular immunity against VZV can be achieved by a subclin-
ical episode of reactivation documented by PCR [7].dgments on page 1019.
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13.04.007VZV has been poorly evaluated, including the presence of
donor-derived or recipient-derived VZV IgG after allogeneic
HSCT. Inherited polymorphisms in IgG heavy chain constant
regions can be recognized by allotype-speciﬁc monoclonal
antibodies and, thus, can be used to distinguish donor and
recipient antibodies [10]. In the present study, we deter-
mined inherited polymorphisms in an IgG allotype, IgG1m(f),
in 50 HSCT donor-recipient pairs and evaluated the status of
donor-derived and recipient-derived VZV IgG production in
12 informative pairs using enzyme-linked immunosorbent
assay (ELISA).PATIENTS AND METHODS
Patients and HSCT Protocol
FiftypatientswhounderwentallogeneicHSCTatour institution fromMarch
2008 to April 2011 andwhowere followedup for at least 1 yearwere evaluated
in this study. The conventional conditioning regimenwasmainly a combination
of cyclophosphamide (60mg/kg for 2 days) and total body irradiation (TBI, 2 Gy
twice daily for 3 days) (n ¼ 26). The reduced-intensity conditioning (RIC)
regimenwasmainlyﬂudarabinecombinedwithmelphalan (low-doseTBI,n¼
14), cyclophosphamide and TBI (ATG, n¼ 5), busulfan (low-dose TBI, n¼ 4),
or only low-dose TBI (n ¼ 1). Standard graft-versus-host disease (GVHD)
prophylaxis consisted of the continuous infusion of cyclosporinewith a starting
dose of 3 mg/kg/day and short-term methotrexate. Each patient provided
written informed consent to be enrolled in the study. This study was approved
by the Institutional Review Board of Jichi Medical University.Transplantation.
Table 1
Patient Information
Characteristic n
Sex (male/female) 28/22
Age, median (range), yr 46.5 (18-65)
Underlying disease
AML 24
ALL 2
CML 1
MDS 2
NHL 4
ATL 6
MM 1
SAA 6
MF 1
Other 3
Stem cell source
PB 19
BM 26
CB 5
Donor type
Matched sibling 15
Mismatched relative 5
Unrelated 30
Conditioning regimen
Conventional 26
RIC 24
IgG1m(f) allotype
Donor (þ) recipient (þ) 3
Donor () recipient (þ) 3
Donor(þ) recipient () 9
Donor() recipient() 35
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome;
NHL, non-Hodgkin lymphoma; ATL, adult T cell leukemia/lymphoma; MM,
multiple myeloma; SAA, severe aplastic anemia; MF, myeloﬁbrosis; PB,
peripheral blood; BM, bone marrow; CB, cord blood; RIC, reduced-intensity
conditioning.
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Acyclovir (ACV) was routinely used as prophylaxis against herpes
simplex virus infection from days -7 to 35. A long-term administration of
low-dose ACV (200 mg/day) for VZV reactivation was started continuously
on day 36 as described previously [11]. ACV was discontinued while gan-
ciclovir or foscarnet was administered for the treatment of cytomegalovirus
infection. ACV administrationwas continued for at least 1 year after HSCT or
longer in patients whowere persistently treated with immunosuppressants.
Diagnosis and Treatment of VZV Disease
The diagnosis of VZV disease was made by the presence of characteristic
vesicular skin lesion on an erythematous base within a dermatome or
a generalized cutaneous distribution. Microbiological and pathological
conformationwas not performed because all cases develop with typical skin
lesions. VZV disease was treated with oral valacyclovir at 3 g/day for 7 days.
ELISA for the IgG Allotype
Plasma specimens of 50 recipients and 20 related donors were available
for IgG allotype testing using an ELISA assay. The 1:2000-diluted mouse
monoclonal antibodies speciﬁc for the G1m(f) allotype (I5385; Sigma, St.
Louis, MO) were coated overnight at 4C on a 96-well microtiter plate (Nunc-
Immuno Plate, PolySorp, Thermo Fisher Scientiﬁc, Rochester, NY). After the
wells were blocked with 200 microliters (mL) of phosphate-buffered saline
with 2% fetal bovine serum for 1 hour, 1:1000-diluted plasma samples were
incubated in duplicate under continuous shaking at room temperature for
2 hours. After 3 washes, 1:2000-diluted peroxidase-conjugated rabbit anti-
human IgG whole molecule (Sigma) was added and incubated for 1 hour at
room temperature. After 3 washes, 100 mL of an ABTS peroxidase substrate
system(KPL,Gaithersburg,MD)was added to eachwell and theplatewas read
with a plate reader at 405 nanometers (nm). The results were evaluated
conveniently by a cut-off index (COI). The COI was calculated as the mean
OD405 froma sampledividedby the cut-off value thatwasdeﬁnedas themean
OD405 of 5 negative controls plus the 2-fold standarddeviation. This assaywas
repeated to evaluate the timing of the appearance of donor-derived IgG or the
disappearance of recipient-derived IgG in 12 allotype-informative patients.
Genotyping
Because plasma samples for ELISA were not available from unrelated
donors, we speculated donor allotype based on the results of ELISA using the
recipients’ plasma samples before and after HSCT. If the recipients were
IgG1m(f)-negative before HSCT (n¼ 24), the allotype of their donors could be
determined as IgG1m(f)-positive when they became IgG1m(f)-positive after
HSCT.However, if the recipientswere IgG1m(f)-positive beforeHSCT (n¼6), it
was impossible to determine the allotype of their donors. Therefore, for
unrelated donorswith IgG1m(f)-positive recipients, the genotypingof human
immunoglobulin heavychain allotypewas carried out as described previously
[12,13] to determine the donorallotype. GenomicDNAwas isolated frompost-
HSCT patients’ peripheral blood after complete donor chimerism was ach-
ieved, with a DNA mini kit (QIAGEN, Valencia, CA). Oligonucleotides PR1
(50 CCCCTGGCACCCTCCTCCAA 30) and PR2 (50 GCCCTGGACTGGGGCTGCAT 30)
were used as the primer set for the ampliﬁcation of a 364-base pair fragment
from the constant region domain of the human IgG1 heavy chain. The
conditions for PCR ampliﬁcation were 94C for 2 minutes followed by 30
cycles of 96C for 1minute, 70C for 30 seconds, 72C for 1minute, and,ﬁnally,
7 minutes of incubation at 72C. The total volume of the PCR mixture was
50 mL, containing 1 mL of genomic DNA, 1 mMMgCl2, 5 units of Platinum taq
DNA polymerase, .2 mM dNTP mix, and .2 mM of each primer. After the
reactionproductswere separated by 2% agarose gel electrophoresis and single
bandswere conﬁrmed, all of the PCR products were puriﬁed using a QIAquick
PCR Puriﬁcation kit (QIAGEN) and sequenced in forward directions using an
ABI 3700 instrument and a BigDye sequencing kit (Applied Biosystems, Foster
City, CA). IgG1m(f) allotypes included arginine residues instead of lysine at
position 214 in theg1 chain of immunoglobulins. This amino acid difference is
due to a single base substitution in the coding DNA (A or G). Meanwhile,
homozygous A of this single nucleotide polymorphism indicates IgG1m(f)
allotype negative; that is, allotype of IgG1m(z). Heterozygous G, heterozygous
A, or homozygous G indicates IgG1m(f) allotype positive.
Measurement of VZV-Speciﬁc and Measles-Speciﬁc IgG after HSCT
Frozen plasma from before HSCT and 6 and 12 months after HSCT were
available for 38 of the 50 patients. Total IgG titers against VZV at these 3
points were monitored by ELISA. A 96-well microtiter plate (Nunc-Immuno
Plate,MaxiSorp) was coatedwith 50 mL of VZV puriﬁed protein (AbD Serotec,
Oxford, United Kingdom) diluted to 5 mg/mL overnight at 4C. After blocking
for 1 hour, 100 mL of patient plasma diluted 1:50 was added to the wells in
duplicate. After incubation at room temperature for 2 hours, the plate was
washed 3 times. Diluted peroxidase-conjugated rabbit antihuman IgG was
added and incubated for 1 hour at room temperature. After 3 washes, anABTS peroxidase substrate systemwas added to each well and the plate was
read with a plate reader at 405 nm. Measles-speciﬁc IgG were analyzed in
the same way using measles virus antigen (Meridian Life Science, Memphis,
TN). The COI was calculated as described above.
To evaluate the magnitude of the serial changes in virus-speciﬁc IgG
titer, a reduction rate for each patient was calculated by dividing the COI at 6
or 12 months after HSCT by the COI before HSCT.
Measurement of VZV-Speciﬁc and Measles-Speciﬁc IgG1m(f)
IgG1m(f) titer against VZV was also monitored sequentially for 12
allotype-informative patients. A 96-well microtiter plate was coated with
50 mL of VZV puriﬁed protein diluted to 5 mg/mL overnight at 4C. After
blocking for 1 hour, 100 mL of patient plasma diluted 1:5 was added to the
wells in duplicate. After incubation at room temperature for 2 hours, the
plate was washed 3 times. The mouse monoclonal antibody speciﬁc for
G1m(f) was added at 1:2000 dilution and incubated for 2 hours at room
temperature, and this was followed by 1 hour of incubationwith peroxidase-
conjugated antimouse IgG whole molecule antibody (A4416; Sigma, 1:2000
dilution). After 3washes, the ABTS peroxidase substrate systemwas added to
each well and the plate was read with a plate reader at 405 nm. Measles-
speciﬁc IgG1m(f) were analyzed in the same way using measles virus
antigen. The COI was calculated as described previously.
Statistical Analysis
The nonparametric Wilcoxon signed rank test and Fisher exact test
were used to evaluate the statistical signiﬁcance of differences in the
IgG1m(f) value and in the incidence of the reduction or disappearance of
virus-speciﬁc IgG. Statistical signiﬁcance in a longitudinal data analysis of
IgG or IgG1m(f) titer was assessed by the Jonckheere-Terpstra test. All
statistical analyses were performed with EZR (SaitamaMedical Center, Jichi
Medical University, Saitama, Japan), which is a graphical user interface for R
version 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria)
[14]. More precisely, it is a modiﬁed version of R commander (version 1.6-3)
that was designed to add statistical functions that are frequently used in
biostatistics.
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IgG Allotype Information and History of VZV Disease
Fifty patient-donor pairs were analyzed with regard to
the IgG allotype. The characteristics of the patients are
shown in Table 1. Twelve pairs were informative because
only the donor (n ¼ 3) or the recipient (n ¼ 9) was homo-
zygous null for the IgG1m(f) allotype by ELISA assay and
genotyping. Among these 12 informative patients, 4 devel-
oped VZV disease after discontinuing ACV administration.
The others showed no clinical episode of VZV reactivation
(Table 2). No patients experienced VZV disease during
administration of low-dose ACV prophylaxis.Appearance of Donor-Derived IgG and Disappearance
of Recipient-Derived IgG after HSCT
Nine homozygous allotypeenull patientswith a IgG1m(f)-
positive donor could be analyzed for the appearance of
donor-derived IgG. One month after HSCT, donor-derived
IgG1m(f) was detected in all but 1 patient. By 1 year after
HSCT, donor-derived IgG1m(f) increased to almost the same
levels as those in healthy donors. One patient who receivedTable 2
Proﬁles of the Twelve Informative Patients with or without VZV Disease
Patients with VZV Disease
Characteristic Patient 1 Pa
Age, yr 58 50
Sex F M
Disease ATL AL
Donor type Unrelated BM Re
Conditioning regimen FLUþMEL TB
Acute GVHD  
Chronic GVHD Oral, eye from d 450 
IgG1m(f) (donor) þ þ
IgG1m(f) (recipient)  
VZV disease d 529 d
d
Use of immunosuppressants at the onset CsA 
Skin region Limited Lim
Treatment Oral VCV Or
Postherpetic neuralgia  þ
Outcome CR Re
Patients without VZV Disease
Characteristic Patient 5 Pa
Age, yr 40 42
Sex M F
Disease CML-BC SA
Donor type unrelated BM un
Conditioning regimen TBIþCY TB
Acute GVHD Grade 2 from d 14 Gr
Chronic GVHD Lung from d 201 Or
IgG1m(f) (donor) þ þ
IgG1m(f) (recipient)  
Characteristic Patient 9 Pa
Age, yr 57 49
Sex M M
Disease AML AM
Donor type Related PB Co
Conditioning regimen FLUþivBU TB
Acute GVHD Grade 2 from d 35 
Chronic GVHD GI, liver from d 137 Or
IgG1m(f) (donor) þ 
IgG1m(f) (recipient)  þ
VZV indicates varicella-zoster virus; M, male; F, female; ATL, adult T cell leuk
lymphoma; AML, acute myeloblastic leukemia; BM, bone marrow; PB, peripheral
body irradiation; GVHD, graft-versus-host disease; d, day; CsA, cyclosporine; VCV
blast crisis; SAA, severe aplastic anemia; ivBU, intravenous busulfan; GI, gastrointeRIC (Patient 8 in Table 2) remained negative for IgG1m(f)
6 months after HSCT (Figure 1A).
Among IgG1m(f)-positive patients with an allotype-null
donor, the recipient-derived IgG1m(f) titer was gradually
reduced, and it became negative by 6 months in 1 patient
who received conventional conditioning (Patient 10 in
Table 2). However, recipient-derived IgG1m(f) remained for
more than 1 year after HSCT in the 2 patients who received
RIC (Patients 11 and 12 in Table 2, Figure 1B).Sequential Changes in VZV-Speciﬁc and
Measles-Speciﬁc IgG
VZV-speciﬁc (n ¼ 39) and measles-speciﬁc (n ¼ 37) IgG
titers after HSCT were analyzed concurrently among patients
for whom sequential plasma samples were available. Two
patients were measles IgG negative before HSCT. Both VZV
and measles IgG titers gradually reduced during the
following year (P ¼ .068 and P < .001, respectively). Measles
antibodies became negative (COI < 1) at 1 year after HSCT in
14 of 37 patients (37.8%), whereas only 5 of 39 patients
(12.8%) became negative for VZV IgG (P¼ .017) (Figure 2A). Intient 2 Patient 3 Patient 4
56 65
F M
L NHL AML
lated PB Cord blood Unrelated BM
IþCY FLUþMELþTBI FLUþMEL
 
 
þ þ
 
-28 and
410
d 720 d 665
 
ited Limited Limited
al VCV Oral VCV Oral VCV
 
lapse at d 230 CR CR
tient 6 Patient 7 Patient 8
31 58
F M
A AML Other
related BM related PB unrelated BM
IþCY TBIþCY FLUþTBI
ade 1 from d 35 Grade 1 from d 26 Grade 1from d 16
al, eye from d 144 Liver from d 188 Muscle from d 125
þ þ
 
tient 10 Patient 11 Patient 12
18 60
F M
L SAA AML
rd blood Related PB Unrelated BM
IþCY FLUþCYþTBI FLUþMEL
 
al, liver from d 219 GI from d 485 Liver from d 201
 
þ þ
emia/lymphoma; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin
blood; FLU, ﬂudarabine; MEL, melphalan; CY, cyclophosphamide; TBI, total
, valacyclovir; CR, complete remission; CML, chronic myeloid leukemia; BC,
stinal.
Figure 1. Serial changes in donor-derived (A) and recipient-derived (B) IgG1m(f) levels after allogeneic HSCT. Expression of the IgG1m(f) allotype was evaluated by an
ELISA assay using anti-IgG1m(f) antibody. The Y-axis shows the cut-off index (COI) that was calculated as the mean OD405 from a sample divided by the cut-off value
deﬁned as the mean OD405 from negative controls plus 2-fold standard deviation.
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before HSCT to those at 6 or 12 months after HSCT between
VZV and measles (Figure 2B). Although both IgG titers were
equivalently reduced by about 20% during the ﬁrst 6 months
(P ¼ .144), the reduction rate of VZV IgG over 12 months was
signiﬁcantly lower than that of measles-IgG (P ¼ .004).Sequential Changes in VZV-Speciﬁc and Measles-Speciﬁc
Donor-Derived IgG1m(f)
Eight of the 9 homozygous-null patients with IgG1m(f)-
positive donors were analyzed sequentially (Figure 3). One
patient (Patient 2 in Table 2) who showed an exceptionally
high VZV IgG titer because of recent VZV infection was
excluded. The COI for both the VZV-speciﬁc and measles-
speciﬁc donor-derived IgG1m(f) remained low, at around
1.0, within 1 year after HSCT, and a signiﬁcant trend for
increased IgG1m(f) was not observed (P ¼ .237 and P ¼ .131,
respectively). However, 3 patients became weakly positive
(COI  1.5) for VZV IgG1m(f) at 6 to 9 months after HSCT.
Thereafter, each of these 3 patients developed VZV disease
after the discontinuation of ACV prophylaxis and the VZV
IgG1m(f) titer was elevated to almost the same level as in
healthy donors.Sequential Changes in VZV-Speciﬁc and Measles-Speciﬁc
Recipient-Derived IgG1m(f)
Three IgG1m(f)-positive patientswith allotype-null donors
were analyzed sequentially. Two patients who underwent
HSCTusing RIC regimens from IgG1m(f) null donors remained
positive for recipient-derived IgG against VZV for over 1 year
after HSCT, whereas in the remaining patient who received
a conventional regimen (Patient 10 in Table 2), recipient-
derived VZV IgG1m(f) titer became undetectable at 1 year
after HSCT. A similar tendency was seen in a measles assay
(data not shown).
Relationship Between the Clinical Course and the Change
in Donor-Derived VZV-Speciﬁc IgG
Serial changes in donor-derived IgG1m(f) against VZV after
HSCT in 4 patientswho developedVZV reactivation are shown
in Figure 4. All of the 4 patients were IgG1m(f) null patients
with IgG1m(f)-positive donors. Patient 1 was a 58-year-old
female with adult T cell leukemia who developed limited
zoster on day 529. Although the donor-derived VZV IgG1m(f)
titer had become weakly positive at around 30 days after
HSCT, the IgG1m(f) titers against VZV were deﬁnitely
elevated after the development of zoster. Patient 2 was a
50-year-old male with acute lymphoblastic leukemia whose
Figure 2. (A) Sequential changes in measles-speciﬁc (left) and varicella-zoster virus (VZV)-speciﬁc (right) IgG levels before and at 6 and 12 months after hemato-
poietic stem cell transplantation (HSCT). Triangles (measles) and circles (VZV) show individual data points. Mean values are shown by black lines. P values represent
Jonckheere-Terpstra test. (B) The reduction rate at 6 (left) and 12 months (right) after HSCT. Box plots show the 25th and 75th percentiles and median values. P values
represent nonparametric Wilcoxon signed rank test.
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after HSCT. He suffered from localized zoster 1 month before
HSCT, which was complicated by severe postherpetic
neuralgia. Although he had a relapse of leukemia at day 230,
VZV IgG1m(f) continued to increase until his second VZV
disease at day 410. Patient 3 was a 56-year-old female with
follicular lymphoma who underwent cord blood trans-
plantation. In this case, although the cord blood donor was
negative for VZV IgG, the VZV IgG1m(f) titers were slightly
elevated at around 3 months after HSCT. These gradually
reduced until the second elevation after VZV disease on day
720. Patient 4 was a 65-year-old female with acute myelo-
blastic leukemiawho developed limited zoster on day 665. As
in Patient 1, the donor-derived VZV IgG1m(f) titer became
weakly positive at around 30 days after HSCT and remained
weakly positive formore than 1 year. Itwas deﬁnitely elevated
after the development of zoster.
DISCUSSION
Allotype-speciﬁc monoclonal antibodies can bind to
single amino acid polymorphisms located in the immuno-
globulin constant region of speciﬁc IgG isotypes. If either the
donor or recipient is homozygous null for an allotype, the
HSCT pair is informative with regard to the origin of anti-
body. This approach has been used to investigate donor-derived humoral immunity reconstitution after allogeneic
HSCT [10]. In the current study, we focused on 1 of the IgG
allotypes, IgG1m(f). Boiko et al. previously examined the
expression of IgG1m(f) and IgG2m(n) in 63 HSCT donor-
recipient pairs, 41% of which were informative [15].
Perhaps because of racial differences and the difﬁculty of
obtaining anti-IgG2m(n) monoclonal antibody, only 12 of the
50 pairs in this study were informative. The allelic frequency
of IgG1m(f) was 18 of 100 samples (18%), which is a slightly
higher frequency than in previous Japanese reports [16,17].
Using such an allotype analysis, van Tol et al. showed the
persistence of recipient-derived IgG at 3 to 8 years after
myeloablative HSCT in a pediatric study [18]. More recently,
Boiko et al. conﬁrmed the persistence of recipient-derived
humoral immunity after allogeneic HSCT using a RIC
regimen by the detection of DNA chimerism in CD38þCD138þ
plasma cells from bone marrow at 12 months after HSCT
[15,19]. In the current study, 2 IgG1m(f)-positive patients
who received a RIC regimen maintained recipient-derived
VZV IgG for more than 1 year after HSCT. This was probably
because of the persistence of recipient-derived plasma
cells [20].
With regard to long-term immunity to various viruses,
Ljungman et al. reported that the probabilities of being
immune to measles at 3, 5, and 7 years after HSCT were 47%,
Figure 3. Sequential changes in measles-speciﬁc (A) and varicella-zoster virus (VZV)-speciﬁc (B) donor-derived IgG1m(f) levels. Gray and black squares indicate
patients with and without VZV disease, respectively. Black lines show the mean values at the same points.
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were 37%, 12%, and 6% for mumps, and 47%, 33%, and 28% for
rubella. They concluded that most allogeneic HSCT patients
will become seronegative to nonlatent viruses during follow-
up and long-term immunity, deﬁned as persistent antibodynot maintained regardless of the immune status of the donor
[21]. However, since VZV is a latent and persistent virus, the
time course of the disappearance of IgG after HSCT may be
different from those of these nonlatent viruses. In our
current analysis, the reduction rate of VZV IgG during
Figure 4. Clinical courses of the 4 IgG1m(f) homozygous-null patients (Patients 1 to 4) who underwent hematopoietic stem cell transplantation (HSCT) from
IgG1m(f)-positive donors and developed varicella-zoster virus (VZV) disease after HSCT. Broken lines show VZV IgG1m(f) levels. CsA indicates cyclosporine; PSL,
prednisolone; ACV, acyclovir; VCV, valacyclovir; GCV, ganciclovir.
R. Yamazaki et al. / Biol Blood Marrow Transplant 19 (2013) 1013e1020 101912 months after HSCT was signiﬁcantly lower than that of
measles-IgG. In addition, 3 patients were weakly positive for
donor-derived VZV IgG1m(f) at 6 to 9 months after HSCT,
including 1 patient who underwent CBT (Patients 1, 3, and 4
in Table 2). This result may indicate that a small amount of
VZV IgG was produced from donor-derived plasma cells that
were continuously stimulated by latent virus antigen. Since
all 3 of these patients subsequently developed VZV disease,
the detection of donor-derived VZV IgG titer under low-dose
ACV may reﬂect the amount of latent viral load and the
possibility of future VZV reactivation. Although low-dose
ACV prophylaxis effectively suppressed VZV reactivation in
our study, the high incidence of VZV disease after ACV
discontinuation still remains to be solved. IgG allotype
analysis might be useful in estimating the risk for zoster after
the discontinuation of low-dose ACV administration. Risk-
adjusted decision-making of low-dose ACV discontinuation
could be useful in reducing the long-term incidence of VZV
reactivation. However, this study is too small and heteroge-
neous to make a deﬁnite conclusion because of the difﬁculty
in collecting informative donor-recipient pairs, and thus, this
hypothesis should be further evaluated in a larger study.
Some previous reports [7,22] hypothesized that the use of
low-dose ACV could permit a subclinical reactivation of VZV,
which may result in the reconstitution of sufﬁcient VZV-
speciﬁc T cell immunity. The ﬁndings in the current study
also support the notion that subclinical VZV reactivationmayexist and induce imperfect VZV-speciﬁc B cell immunity.
However, without symptomatic VZV reactivation, donor-
derived anti-VZV IgG did not reach titers comparable to
those measured in healthy virus carriers.
Notably, donor-derived VZV IgG elevated vigorously in
the early phase after HSCT in a patient who developed zoster
just before allogeneic HSCT. Processed antigen presented
on chemo-radiationeresistant recipient antigen-presenting
cells might stimulate transferred donor B cells. Vaccination
of the recipients before allogeneic HSCT may accelerate the
reconstitution of donor-derived VZV IgG.
In conclusion, the production of anti-VZV IgG by recipient
plasma cells persists long after RIC transplantation. In patients
without symptomatic VZV reactivation, donor-derived anti-
VZV IgG did not reach titers comparable to those measured in
healthy virus carriers.
ACKNOWLEDGMENTS
Financial disclosure: This work was supported in part by
a Jichi Medical University Young Investigator Award.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
REFERENCES
1. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after
bone marrow transplantation: incidence, risk factors and complica-
tions. Bone Marrow Transplant. 1994;13:277-283.
R. Yamazaki et al. / Biol Blood Marrow Transplant 19 (2013) 1013e102010202. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections
following allogeneic bone marrow transplantation: frequency, risk
factors, and clinical outcome. Biol Blood Marrow Transplant. 2000;6:
44-49.
3. Arvin AM. Varicella-Zoster virus: pathogenesis, immunity, and clinical
management in hematopoietic cell transplant recipients. Biol Blood
Marrow Transplant. 2000;6:219-230.
4. Tomonari A, Iseki T, Takahashi S, et al. Varicella-zoster virus infec-
tion in adult patients after unrelated cord blood transplantation:
a single institute experience in Japan. Br J Haematol. 2003;122:
802-805.
5. Arvin AM. Immune responses to varicella-zoster virus. Infect Dis Clin
North Am. 1996;10:529-570.
6. Ljungman P, Lonnqvist B, Gahrton G, et al. Clinical and subclinical
reactivations of varicella-zoster virus in immunocompromised
patients. J Infect Dis. 1986;153:840-847.
7. Wilson A, Sharp M, Koropchak CM, et al. Subclinical varicella-zoster
virus viremia, herpes zoster, and T lymphocyte immunity to varicella-
zoster viral antigens after bone marrow transplantation. J Infect Dis.
1992;165:119-126.
8. Kato S, Yabe H, Yabe M, et al. Studies on transfer of varicella-zoster-
virus speciﬁc T-cell immunity from bone marrow donor to recipient.
Blood. 1990;75:806-809.
9. Distler E, Schnurer E, Wagner E, et al. Recovery of varicella-zoster
virus-speciﬁc T cell immunity after T cell-depleted allogeneic trans-
plantation requires symptomatic virus reactivation. Biol Blood Marrow
Transplant. 2008;14:1417-1424.
10. Witherspoon RP, Schanﬁeld MS, Storb R, et al. Immunoglobulin
production of donor origin after marrow transplantation for acute
leukemia or aplastic anemia. Transplantation. 1978;26:407-408.
11. Asano-Mori Y, Kanda Y, Oshima K, et al. Long-term ultra-low-dose
acyclovir against varicella-zoster virus reactivation after allogeneic
hematopoietic stem cell transplantation. Am J Hematol. 2008;83:
472-476.12. Balbin M, Grubb A, Abrahamson M, Grubb R. Determination of allo-
types G1m(f) and G1m(z) at the genomic level by subclass-speciﬁc
ampliﬁcation of DNA and use of allele-speciﬁc probes. Exp Clin Immu-
nogenet. 1991;8:88-95.
13. Yamazaki R, Nakasone H, Wada H, et al. Recurrence of monoclonal
gammopathy associatedwith donor-derivedmyelodysplastic syndrome
after cord blood stem cell transplantation. Exp Hematol. 2011;39:
1119-1123.
14. Kanda Y. Investigation of the freely available easy-to-use software ’EZR’
for medical statistics. Bone Marrow Transplant. 2013;48:452-458.
15. Boiko JR SB, Mueller A, Chen GL, et al. IgG allotypes reveal that anti-
mirobial humoral immunity persists after reduced-intensity hemato-
poietic cell transplantation. ASH Anual Meeting Abstracts 2008;112;
abstract 349.
16. Kameda H, Pandey JP, Kaburaki J, et al. Immunoglobulin allotype gene
polymorphisms in systemic sclerosis: interactive effect of MHC class II
and KM genes on anticentromere antibody production. Ann Rheum Dis.
1998;57:366-370.
17. Nakao Y, Matsumoto H, Miyazaki T, et al. IgG heavy chain allotypes
(Gm) in autoimmune diseases. Clin Exp Immunol. 1980;42:20-26.
18. van Tol MJ, Gerritsen EJ, de Lange GG, et al. The origin of IgG produc-
tion and homogeneous IgG components after allogeneic bone marrow
transplantation. Blood. 1996;87:818-826.
19. Small TN, Robinson WH, Miklos DB. B cells and transplantation: an
educational resource. Biol Blood Marrow Transplant. 2009;15:104-113.
20. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to
long-lived plasma cells. Immunity. 1998;8:363-372.
21. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, et al. Long-term
immunity to measles, mumps, and rubella after allogeneic bone
marrow transplantation. Blood. 1994;84:657-663.
22. Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for
prevention of varicella zoster virus disease after allogeneic hemato-
poietic cell transplantationea randomized double-blind placebo-
controlled study. Blood. 2006;107:1800-1805.
